EMERYVILLE, Calif.–()–Ansa Biotechnologies, a pioneer of next-generation DNA synthesis, today announced the appointment of Matthew F. McManus, M.D, Ph.D., as Independent Director and Chairperson of the company’s Board of Directors.

Dr. McManus brings decades of experience in the life sciences industry to the Board. He was most recently EVP and Chief Operating Officer at Azenta (NASDAQ:AZTA), a global life sciences tools, products, and services company. Prior to Azenta, Dr. McManus was Senior Vice President and General Manager of the Molecular Diagnostics Division at Bio-Techne following its acquisition of Asuragen, where he served as President and CEO and led the strategic transformation of the business into a profitable global molecular diagnostics company. Previously, Dr. McManus was the President and CEO of PrimeraDx, a company that developed and commercialized a novel molecular diagnostics instrument platform and was acquired by Qiagen.

“We’re thrilled to welcome Matt to the Board as we enter our next stage of growth,” said Daniel Lin-Arlow, CEO & Co-Founder. “His extensive life sciences products and services commercialization expertise will be invaluable as we bring our long-write DNA synthesis technology to market.”

“Ansa’s proprietary DNA synthesis technology will power future innovations in medicine, agriculture, industrial biology, and other applications,” McManus said. “I am honored to have the opportunity to work with the Ansa Bio team to help realize this potential.”

Dr. McManus received his M.D. and Ph.D. from the University of Pennsylvania, his MBA from Boston College and his B.A. in Economics from College of the Holy Cross.

About Ansa Biotechnologies

Ansa Biotechnologies is building a fast and reliable DNA synthesis service to accelerate synthetic biology research. Our core technology is a novel DNA synthesis method based on enzymes that is faster, cleaner, and more accurate than existing methods. For more information, visit ansabio.com or follow on Twitter and LinkedIn.

For partnering inquiries or information about Ansa’s early access program, email DNA@ansabio.com.